Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

BIOXPLOR

Financiado

Cerrado

BioXplor s AI Cognitive Software Platform accelerates and greatly reduces the co...

BioXplor s AI Cognitive Software Platform accelerates and greatly reduces the cost of discovery research and clinical trials with a primary focus on rare and inflammatory diseases data. BioXplor’s AI/Cognitive Software Platform accelerates and greatly reduces the cost of discovery research and clinical trials, with a primary focus on rare and inflammatory diseases data. The technology has shown a 5-25x reduction... ver más

30/11/2019

BioXplor Ltd

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

BIOXPLOR LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-11-30

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

BioXplor Ltd

50.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

REPO4EU Precision drug REPurpOsing For EUrope and the world 23M€ Cerrado

Symptoma Symptoma Better Diagnosis for Patients with Rare and Comple... 2M€ Cerrado

NADIR New directions for deep learning in cancer research through... 1M€ Cerrado

H-GET Hypothesis generation evaluation and testing An organic d... 253K€ Cerrado

TED2021-129974B-C21 OPTIMIZACION DE UN DATALAKE CLINICO MEDIANTE LA INCORPORACIO... 288K€ Cerrado

PredictND From Patient Data to Clinical Diagnosis in Neurodegenerative... 4M€ Cerrado

Duración del proyecto: 3 meses Fecha Inicio: 2019-07-31
Fecha Fin: 2019-11-30

Líder del proyecto

BIOXPLOR LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto BioXplor’s AI/Cognitive Software Platform accelerates and greatly reduces the cost of discovery research and clinical trials, with a primary focus on rare and inflammatory diseases data. The technology has shown a 5-25x reduction in time and 70% cost savings in pilots so far. (TLR stage 6 &7 tests in 5x Biotech and Pharma companies). BioXplor has achieved the Seal of Excellence for our Phase I application in March 2019 (score 13.5) and November 2018 (score 13.09) submissions. Last year, we have been completed acceleration programs at UC Berkeley’s SkyDeck and at Merck, and since then significant progress in building the platform to TLR stage 7 and acquiring new customers and revenue. The platform has been successfully used in tests with 5x Pharma and biotech companies (Merck, Bayer, Novartis, Abcam, EdemedX), and we have 5 new leads, for our platform for Discovery applications (antibodies, recombinant proteins, biomarker discovery, immunoassays, drug target ID) and Clinical applications (indication expansion, super-responder ID for drug-repositioning, and patient stratification for Biosimilars, all in inflammation projects with Biotech and Pharma). The current submission is aimed towards bringing BioXplor’s Platform to TLR stage 8, and deploying the our fully tested solution in operational environments at Pharma, Biotech and Academic Research Institutes, for which we are already negotiating pre-orders including 3 year multiyear contracts and 5-10 year partnerships. We have since partnered UC Berkeley, gained access to clinical trials patient data from a major pharma, become a discovery forum member with the 100K Genomes Project, and been selected as a consortium partner for an EU project in the oncology space. We have built a pipeline of EUR750k, with 2019 revenues projected at EUR500k and project revenues of $2M by 2021. We have been requested to deliver the solution to manage 15-20 clinical trials (secondary use of data) for a Top 2 Pharma company

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores